Compare GPCR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPCR | RCUS |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2023 | 2018 |
| Metric | GPCR | RCUS |
|---|---|---|
| Price | $38.79 | $24.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $103.17 | $31.90 |
| AVG Volume (30 Days) | 755.9K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.04 | $11.30 |
| 52 Week High | $94.90 | $31.74 |
| Indicator | GPCR | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 27.86 | 33.18 |
| Support Level | $36.11 | $25.94 |
| Resistance Level | $41.50 | $26.43 |
| Average True Range (ATR) | 2.45 | 1.22 |
| MACD | -1.11 | -0.38 |
| Stochastic Oscillator | 2.07 | 0.00 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.